Secondary Prevention clinical trials at UC Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.
at UC Davis